11 May 2022 | News
Obtains CE mark for the ovarian cancer product
image credit- prnewswire
Known as a pioneer in Asia's women's and foetal health industry, Singapore-based diagnostics developer, INEX Innovate has obtained a CE mark for its lead ovarian cancer product, the OvaCis Rapid Test.
Slated to launch in the EU and Southeast Asian markets by the end of 2022, OvaCis is a first of its kind point-of-care (POCT) test that discriminates benign from malignant ovarian cysts in an operating theatre setting.
OvaCis Rapid Test works by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant. The test was developed as a rapid test format, and has proved to be user friendly requiring only minimal training and 5 minutes of hands-on time.
Emerging from the National University of Singapore (NUS), INEX was founded by veteran maternal fetal medicine specialists. Backed by institutional investors, it is uniquely positioned to identify and address clinically unmet needs within women's and fetal health landscape. The company focuses on developing and translating technologies that aim to deliver precision healthcare for women in Asia.